Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Comment by EternalPonzion Jan 13, 2020 12:06pm
110 Views
Post# 30546683

RE:RE:Clearly an OVER Reaction

RE:RE:Clearly an OVER Reaction
Capitulation. Apparently 20 of the largest shareholders own a bit less than 50% which means some of them have probably bailed, but there is no doubt a ton of HF day trading happening. As I stated previously, lawsuits are pending if results are found to be flawed. If there was any question as to the veracity of the results they should not have been released. The company has set themselves up for major legal problems now. Would have been better to halt the stock pending verification of the results. Allowing trading on inaccurate or bad info is not what is suppose to happen. Perhaps 23 Dec delay was for that purpose. Next 6 - 8 weeks critical. In short term, stock either going back to $3- $4 range (if Trilogy 2 results very favorable and Trilogy 1 results plausibly figured out with good secondaries) or about 20 cents (Trilogy 2 results similar to T1) as company will have to call it a day and buy back shares with their remaining funds. Won't that be fun.
Bullboard Posts